Clinical Trial Update: A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares 24-week versus 48-week courses of pegylated interferon plus ribavirin for hepatitis C genotype-6; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED